Autotransplants in multiple myeloma: What have we learned?

Blood

Volumn 88, Issue 3, 1996, Pages 838-847

  Vesole, David H ^a   Tricot, Guido ^a   Jagannath, Sundar ^a   Desikan, K R ^a   Siegel, David ^a   Bracy, Dwayne ^a   Miller, Langdon ^a   Cheson, Bruce ^a   Crowley, John ^a   Barlogie, Bart ^a  

^a Mail Slot 508 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA 2 MICROGLOBULIN; BUSULFAN; C REACTIVE PROTEIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; THIOTEPA; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CHROMOSOME 11Q; CHROMOSOME 13; CHROMOSOME DELETION; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; WHOLE BODY RADIATION;

EID: 0344813041     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.838.838     Document Type: Article

References (53)

1. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma - New biological insights and advances in therapy. Blood 73:865, 1989
2. Blade J, Lopez-Guillermo A, Bosch F, Cervantes F, Reverter J-C, Montserrat EM, Rozman C: Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients. Br J Haematol 88:117, 1994
3. Barlogie B, Alexanian R, Jagannath S: Plasma cell dyscrasias. JAMA 268:2946, 1992
4. Kyle RA: Long-term survival in multiple myeloma. N Engl J Med 308:314, 1983
5. Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C, Kawato M, Takagi T, Towawa A, Isobe T, Suzuki K, Imamura Y, Takatsuki K: Ten-year survival and prognostic factors in multiple myeloma. Br J Haematol 87:832, 1994
6. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F: Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 72:2015, 1988
7. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, Norman A, Raymond J, Powles R: High-dose melphalan for multiple myeloma: Long-term follow-up data. J Clin Oncol 12:764, 1994
8. Lokhorst HM, Meuwissen OJA Th, Verdonck LF, Dekker AW: High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 10:47, 1992
9. Jagannath S, Vesole D, Glenn L, Crowley J, Barlogie B: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666, 1992
10. Attal M, Huguel F, Schlaifer D, Payen C, Laroche M. Fournie B, Mazieres B, Pris J, Laurent G: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79:1130, 1992
11. Fermand J, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F. Mariette X, Brouet J: High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 82:2005, 1993
12. Harousseau J, Milpied N, Laporte J, Collombat P, Facon T, Tigaud J, Casassus P, Guilhot F, Ifrah N, Grandhour C: Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827, 1992
13. Dimopolous M, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, Van Besien K, Delasalle K, Reading C, Deisseroth A, Champlin R: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324, 1993
14. Barlogie B, Jagannath S, Vesole D, Tricot G, Naucke S, Copeland N, Crowley J: Total therapy for newly diagnosed multiple myeloma. Blood 82:198a, 1993 (abstr, suppl 1)
15. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J, Slevin M, Findlay M, Raymond J, Gore ME: High-dose melphalan and antologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759, 1994
16. Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon S, Barlogie B: Hemopoietic stem cell transplants for multiple myeloma. Oncology 8:89, 1994
17. Harousseau J-L, Attal M, Divine M, Marit G, Leblond V, Stoppa A-M, Bourhis J-H, Caillot D, Boasson M, Abgrall J-F, Facon T, Linassier C, Cahn J-Y, Lamy T, Troussard X, Gratecos N, Pignon B, Auzanneau G, Bataille R: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Blood 85:3077, 1995
18. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley B, Barlogie B: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588, 1995
19. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353, 1984
20. Barlogie B, Velasquez WS, Alexanian R, Cabanillas F: Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 7:1514, 1989
21. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137, 1993
22. Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, Barlogie B: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
23. Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C: A randomized clinical trial comparing melphalan/prednisone with or without Interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study. J Clin Oncol 11:155, 1993
24. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Comotti B, Dammacco F, Frieri R, Gallamini A, Gallone G, Giovangrossi P, Grignani F, Lauta VM, Liberati M, Musto P, Neretto G, Petrucci MT, Resegotti L, Pileri A, Mandelli F: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9:444, 1991
25. MacLennan ICM, Chapman C, Dunn J, Kelly K: Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 339:200, 1992
26. Osterborg A, Bjorkholm M, Bjoreman M, Brenning F, Carlson K, Celsing F, Gahrton G, Grimfors G, Gyllenhammar H, Hast R, Johansson B, Juliusson G, Jarnmark M, Kimby E, Lerner R, Linder O, Merk K, Nilsson B, Ohrling M, Paul C, Simonsson B, Smedmyr B, Svedmyr E, Stalfelt A-M, Strander H, Uden A-M, Osby E, Mellstedt H: Natural interferon-a in combination with melphalan/ prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood 81:1428, 1993
27. Tricot G, Barlogie B, Jagannath S, Vesole D, Naucke S, Tian E, Gazitt Y: Double antotransplants can induce molecular remissions (MCR) in newly diagnosed patients with multiple myeloma (MM). Blood 86:769a, 1995 (suppl 1, abstr)
28. Owen RG, Bybee A, Haynes AP, Johnson RJ, Smith GM, Child JA, Russell NH, Gupta D, Samson D, Morgan GJ: PCR monitoring following transplantation in multiple myeloma. Blood 86:208a, 1995 (suppl 1, abstr)
29. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G: Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 15:367, 1995
30. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA: Prognostic value of pretreatment serum β2 microglobulin in myeloma: A Southwest Oncology Group study. Blood 75:823, 1990
31. Greipp PR, Lust JA, O'Fallon M, Katzmann JA, Witzig TE, Kyle RA: Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382, 1993
32. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J: High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950, 1994
33. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, Auzanneau G, Blade J, Brunet S, Carlson K, Cavo M, Ferrant A, Gravett P, De Laurenzi A, Prentice HG, Proctor S, Remes K, Troussard X, Verdonck LF, Williams C, Gahrton G: Autologous stem cell transplantation in multiple myeloma: Results of the European Group for Bone Marrow Transplantation. Stem Cells 13:140, 1995
34. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B: Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. Bone Marrow Transplant 16:7, 1995
35. Gregory W, Richards M, Malpas J: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334, 1992
36. Tricot G, Vesole D, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996
37. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, Casassus P, Thyss A, Maisonneuve H, Facon T, Ifrah N, Paven C, Bataille R: High dose therapy in multiple myeloma: Final analysis of a prospective randomized study of the "Intergroupe Francais du Myelome" (IFM 90). Blood 86:124a, 1995 (suppl 1, abstr)
38. Barlogie B, Crowley J, Jagannath S, Vesole D, Tricot G, Jacobson J, Salmon S: Superior outcome after early autotransplantation (AT) with "Total Therapy" (TT) compared to standard SWOG treatment (ST) for multiple myeloma (MM). Blood 86:207a, 1995 (abstr, suppl 1)
39. Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, Facon T, Colombat P, Cahn JY, Lamy T, Troussard X, Gratecos N, Pignon B, Auzanneau G: Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 15:963, 1995
40. Henon P, Donatini B, Eisenmann JC, Becker M, Beck-Wirth G: Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 16:19, 1995
41. Alexanian R, Dimopolous M, Smith T, Delasalle K, Barlogie B, Champlin R: Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512, 1994
42. Alexanian R, Dimopolous MA, Hester J, Delasalle K, Champlin R: Early myeloablative therapy for multiple myeloma. Blood 84:4278, 1994
43. Tricot G, Alberts DS, Johnson CS, Roe DJ, Dorr RT, Vesole DH, Jagannath S, Meyers R, Barlogie B: Safety of autotransplants with high dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res (in press)
44. Jagannath S, Vesole D, Tricot G, Barlogie B: 118 Outpatient (OPT) autotransplants in multiple myeloma (MM). Blood 84:212a, 1994 (suppl 1, abstr)
45. Powles R, Mehta J, Singhal S, Horton C, Tait D, Milan S, Pollard C, Lumley H, Matthey F, Shirley J, Williams H, Samaratunga I, Lakhani A, Millar J, Treleaven J: Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. Bone Marrow Transplant 16:241, 1995
46. Gazitt Y, Tian E, Barlogie B, Reading CC, Vesole D, Jagannath S, Schnell J, Hoffman R, Tricot G: Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma following treatment with cyclophosphamide and GM-CSF. Blood 87:805, 1996
47. Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR: The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 84:3283, 1994
48. + stem cells do not contain clonal myeloma cells. Blood 86:381, 1995
49. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390, 1995
50. - peripheral blood stem cells (PBSC) effect timely trilineage engraftment in multiple myeloma (MM). Blood 86:293a, 1995 (suppl 1, abstr)
51. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F: Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84:2158, 1994
52. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant J-P, Sauvage C, Troussard X, Nedellec G, Pico J, Huguet F, Stoppa AM, Broustet A, Sotto J-J, Pris J, Maraninchi D, Reiffers J: Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 86:1619, 1995
53. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1991